OSE Immunotherapeutics Management

Management criteria checks 4/4

OSE Immunotherapeutics' CEO is Nicolas Poirier, appointed in Jan 2016, has a tenure of 7.33 years. directly owns 1.04% of the company’s shares, worth €724.94K. The average tenure of the management team and the board of directors is 4.4 years and 6.5 years respectively.

Key information

Nicolas Poirier

Chief executive officer

€17.8k

Total compensation

CEO salary percentage	n/a
CEO tenure	7.3yrs
CEO ownership	1.0%
Management average tenure	4.4yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO

Nicolas Poirier (40 yo)

7.3yrs

Tenure

€17,811

Compensation

Dr. Nicolas Poirier, PhD, has been the Chief Scientific Officer of OSE Immunotherapeutics SA since 2016 and serves as its Director from June 26, 2019 and also serves as its Chief Executive Officer from Oct...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dominique Costantini	Founder	11.1yrs	€459.62k	10.86% € 7.5m
Nicolas Poirier	CEO, Chief Scientific Officer & Director	7.3yrs	€17.81k	1.04% € 724.9k
Alexis Peyroles	Consultant	1.3yrs	€586.59k	4.97% € 3.5m
Anne-Laure Autret-Cornet	Chief Financial Officer	no data	no data	no data
Alain Chatelin	Medical Director	no data	no data	no data
Jean-Pascal Conduzorgues	Chief Manufacturing Officer & Qualified Person (QP)	no data	no data	no data
Bérangère Vasseur	Chief Medical Officer Immuno-Oncology	5.3yrs	no data	no data
Julien Perrier	Chief Commercial Officer	4.4yrs	no data	no data
Linda Lebon	Chief Regulatory Officer	1.4yrs	no data	no data
Silvia Comis	Head of Clinical Development	1.4yrs	no data	no data

4.4yrs

Average Tenure

51.5yo

Average Age

Experienced Management: OSEP's management team is considered experienced (4.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dominique Costantini	Founder	11.1yrs	€459.62k	10.86% € 7.5m
Nicolas Poirier	CEO, Chief Scientific Officer & Director	3.9yrs	€17.81k	1.04% € 724.9k
Maryvonne Hiance	Vice Chairwoman	7yrs	€22.72k	2.29% € 1.6m
Jean-Patrick Demonsang	Independent Director	9.1yrs	€34.29k	0.16% € 112.8k
Bernard Malissen	Member of Scientific Advisory Board	less than a year	no data	no data
Alexandre Lebeaut	Independent Director	1.3yrs	no data	no data
Sophie Brouard	Member of the Scientific Advisory Board	less than a year	€25.71k	1.1% € 762.9k
Brigitte Dreno	Independent Director	5.9yrs	€21.43k	no data
Gérard Tobelem	Independent Director	9.1yrs	€34.29k	0.17% € 117.5k
Didier Hoch	Independent Director	7yrs	€30.86k	0.040% € 27.6k
Wolf-Herve Fridman	Chairman of the Scientific Board	9.5yrs	no data	no data
Elsy Boglioli	Independent Director	1.9yrs	€102.86k	no data

6.5yrs

Average Tenure

66.5yo

Average Age

Experienced Board: OSEP's board of directors are considered experienced (6.5 years average tenure).

OSE Immunotherapeutics Management

Management criteria checks 4/4

Key information

Recent management updates

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022

OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board

Recent updates

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody

OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation

OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

OSE Immunotherapeutics SA Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announces Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer

OSE Immunotherapeutics SA Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas

OSE Immunotherapeutics SA Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

Ose Immunotherapeutics Announces Publication of Peer-Reviewed Data on Clec-1

Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome

OSE Immunotherapeutics SA Updates on Tedopi®, Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

First half 2022 earnings released: €0.11 loss per share (vs €0.64 loss in 1H 2021)

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022

OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

OSE Immunotherapeutics SA Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

No longer forecast to breakeven

OSE Immunotherapeutics SA to Report Fiscal Year 2021 Results on Mar 30, 2022

Boehringer Ingelheim and OSE Immunotherapeutics to Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

OSE Immunotherapeutics SA Appoints Alexandre Lebeaut as Independent Member of the Board of Directors

OSE Immunotherapeutics SA Announces Acceptance of the US Investigational New Drug Application Obtained by Veloxis Pharmaceuticals, Inc., Its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age